Memantine for Cognitive and Adaptive Outcome Measures in Young People With Down Syndrome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial
Lancet Neurol 2022 Jan 01;21(1)31-41, ACS Costa, AC Brandão, R Boada, VL Barrionuevo, HG Taylor, E Roth, MR Stasko, MW Johnson, FF Assir, MP Roberto, P Salmona, G Abreu-Silveira, I Bederman, E Prendergast, A Hüls, S Abrishamcar, Z Mustacchi, T Scheidemantel, NJ Roizen, S RuedrichFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.